MicroRNA-34a inhibits the proliferation and promotes the apoptosis of non-small cell lung cancer H1299 cell line by targeting TGFβR2

Tumor Biology

Volumn 36, Issue 4, 2015, Pages 2481-2490

  Ma, Zhong Liang ^a,b,c,d   Hou, Pin Pin ^a,b,c,d   Li, Yan Li ^a,b,c,d   Wang, De Tao ^a,b,c,d   Yuan, Tian Wei ^a,b,c,d   Wei, Jia Li ^a,b,c,d   Zhao, Bo Tao ^a,b,c,d   Lou, Jia Tao ^a,b,c,d   Zhao, Xin Tai ^a,b,c,d   Jin, Yan ^a,b,c,d   Jin, You Xin ^a,b,c,d  

^a SHANGHAI UNIVERSITY   (China)

^b SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY   (China)

^c SHANGHAI CHEST HOSPITAL   (China)

^d Mfg Co Ltd   (China)

Author keywords

Apoptosis; miR 34a; Non small cell lung cancer; Proliferation; TGF R2

Indexed keywords

3' UNTRANSLATED REGION; MESSENGER RNA; MICRORNA; MIRN34 MICRORNA, HUMAN; PROTEIN SERINE THREONINE KINASE; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR;

3' UNTRANSLATED REGION; APOPTOSIS; BIOSYNTHESIS; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; NON SMALL CELL LUNG CANCER; PATHOLOGY; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 84935520556     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2861-5     Document Type: Article

References (44)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: Cancer J Clin. 2011;61:69–90. doi:10.3322/caac.20107.
2. Marchevsky AM, Gal AA, Shah S, Koss MN. Morphometry confirms the presence of considerable nuclear size overlap between “small cells” and “large cells” in high-grade pulmonary neuroendocrine neoplasms. Am J Clin Pathol. 2001;116:466–72. doi:10.1309/H40B-8W14-4Q47-03EP.
3. Fassina A, Cappellesso R, Fassan M. Classification of non-small cell lung carcinoma in transthoracic needle specimens using microrna expression profiling. Chest. 2011;140:1305–11. doi:10.1378/chest. 11-0708.
4. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol. 2009;11:228–34. doi:10.1038/ncb0309-228.
5. Peter ME. Let-7 and mir-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle. 2009;8:843–52.
6. Hu J, Xu J, Wu Y, Chen Q, Zheng W, Lu X, et al. Identification of microRNA-93 as a functional dysregulated miRNA in triple-negative breast cancer. Tumour Biol: J Int Soc Oncodevelop Biol Med. 2014. doi:10.1007/s13277-014-2611-8.
7. Tiwari A, Shivananda S, Gopinath KS, Kumar A. MicroRNA-125a reduces proliferation and invasion of oral squamous cell carcinoma cells by targeting estrogen-related receptor alpha: implications for cancer therapeutics. J Biol Chem. 2014. doi:10.1074/jbc.M114.584136.
8. Gade S, Porzelius C, Falth M, Brase JC, Wuttig D, Kuner R, et al. Graph based fusion of miRNA and mRNA expression data improves clinical outcome prediction in prostate cancer. BMC Bioinforma. 2011;12:488. doi:10.1186/1471-2105-12-488.
9. Silber J, James CD, Hodgson JG. MicroRNAs in gliomas: small regulators of a big problem. Neruomol Med. 2009;11:208–22. doi:10.1007/s12017-009-8087-9.
10. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004;101:2999–3004. doi:10.1073/pnas.0307323101.
11. Leman ES, Magheli A, Yong KM, Netto G, Hinz S, Getzenberg RH. Identification of nuclear structural protein alterations associated with seminomas. J Cell Biochem. 2009;108:1274–9. doi:10.1002/jcb.22357.
12. Debey-Pascher S, Chen J, Voss T, Staratschek-Jox A. Blood-based mirna preparation for noninvasive biomarker development. Methods Mol Biol. 2012;822:307–38. doi:10.1007/978-1-61779-427-8_22.
13. D’Haene B, Mestdagh P, Hellemans J, Vandesompele J. MiRNA expression profiling: from reference genes to global mean normalization. Methods Mol Biol. 2012;822:261–72. doi:10.1007/978-1-61779-427-8_18.
14. Chen J, April CS, Fan JB. Mirna expression profiling using illumina universal beadchips. Methods Mol Biol. 2012;822:103–16. doi:10.1007/978-1-61779-427-8_7.
15. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, et al. A microRNA component of the p53 tumour suppressor network. Nature. 2007;447:1130–4. doi:10.1038/nature05939.
16. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, et al. Transactivation of mir-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007;26:745–52. doi:10.1016/j.molcel.2007.05.010.
17. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, et al. Transcriptional activation of mir-34a contributes to p53-mediated apoptosis. Mol Cell. 2007;26:731–43. doi:10.1016/j.molcel.2007.05.017.
18. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, et al. P53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol: CB. 2007;17:1298–307. doi:10.1016/j.cub.2007.06.068.
19. Menendez D, Inga A, Resnick MA. The expanding universe of p53 targets. Nat Rev Cancer. 2009;9:724–37. doi:10.1038/nrc2730.
20. Wang DT, Ma ZL, Li YL, Wang YQ, Zhao BT, Wei JL, et al. Mir-150, p53 protein and relevant miRNAs consist of a regulatory network in NSCLC tumorigenesis. Oncol Rep. 2013;30:492–8. doi:10.3892/or.2013.2453.
21. Schultz N, Marenstein DR, De Angelis DA, Wang WQ, Nelander S, Jacobsen A, et al. Off-target effects dominate a large-scale RNAi screen for modulators of the TGF-beta pathway and reveal microRNA regulation of TGFβR2. Silence. 2011;2:3. doi:10.1186/1758-907X-2-3.
22. Kubiczkova L, Sedlarikova L, Hajek R, Sevcikova S. TGF-beta—an excellent servant but a bad master. J Transl Med. 2012;10:183. doi:10.1186/1479-5876-10-183.
23. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet. 2001;29:117–29. doi:10.1038/ng1001-117.
24. Massague J. TGFbeta in cancer. Cell. 2008;134:215–30. doi:10.1016/j.cell.2008.07.001.
25. Zhang HT, Chen XF, Wang MH, Wang JC, Qi QY, Zhang RM, et al. Defective expression of transforming growth factor beta receptor type II is associated with cpg methylated promoter in primary non-small cell lung cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2004;10:2359–67.
26. Xu CC, Wu LM, Sun W, Zhang N, Chen WS, Fu XN. Effects of TGF-beta signaling blockade on human a549 lung adenocarcinoma cell lines. Mol Med Rep. 2011;4:1007–15. doi:10.3892/mmr.2011.530.
27. Zhang JX, Han L, Bao ZS, Wang YY, Chen LY, Yan W, et al. Hotair, a cell cycle-associated long noncoding RNA and a strong predictor of survival, is preferentially expressed in classical and mesenchymal glioma. Neuro-Oncology. 2013;15:1595–603. doi:10.1093/neuonc/not131.
28. Lu L, Katsaros D, Zhu Y, Hoffman A, Luca S, Marion CE, et al. Let-7a regulation of insulin-like growth factors in breast cancer. Breast Cancer Res Treat. 2011;126:687–94. doi:10.1007/s10549-010-1168-5.
29. Lu L, Katsaros D, de la Longrais IA, Sochirca O, Yu H. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res. 2007;67:10117–22. doi:10.1158/0008-5472.CAN-07-2544.
30. Vogt M, Munding J, Gruner M, Liffers ST, Verdoodt B, Hauk J, et al. Frequent concomitant inactivation of mir-34a and mir-34b/c by cpg methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Archiv: Int J Pathol. 2011;458:313–22. doi:10.1007/s00428-010-1030-5.
31. Chen F, Hu SJ. Effect of microRNA-34a in cell cycle, differentiation, and apoptosis: a review. J Biochem Mol Toxicol. 2012;26:79–86. doi:10.1002/jbt.20412.
32. Yang S, Li Y, Gao J, Zhang T, Li S, Luo A, et al. MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting fra-1. Oncogene. 2013;32:4294–303. doi:10.1038/onc.2012.432.
33. Yan K, Gao J, Yang T, Ma Q, Qiu X, Fan Q, et al. MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo. PLoS One. 2012;7:e33778. doi:10.1371/journal.pone.0033778.
34. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D, et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 2010;70:5923–30. doi:10.1158/0008-5472.CAN-10-0655.
35. Bandi N, Vassella E. Mir-34a and mir-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and rb-dependent manner. Mol Cancer. 2011;10:55. doi:10.1186/1476-4598-10-55.
36. Shi Y, Liu C, Liu X, Tang DG, Wang J. The microRNA mir-34a inhibits non-small cell lung cancer (NSCLC) growth and the cd44hi stem-like NSCLC cells. PLoS One. 2014;9:e90022. doi:10.1371/journal.pone.0090022.
37. Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E, et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res. 2009;69:7569–76. doi:10.1158/0008-5472.CAN-09-0529.
38. Wei JS, Song YK, Durinck S, Chen QR, Cheuk AT, Tsang P, et al. The mycn oncogene is a direct target of mir-34a. Oncogene. 2008;27:5204–13. doi:10.1038/onc.2008.154.
39. Welch C, Chen Y, Stallings RL. Microrna-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene. 2007;26:5017–22. doi:10.1038/sj.onc.1210293.
40. Sun F, Fu H, Liu Q, Tie Y, Zhu J, Xing R, et al. Downregulation of ccnd1 and cdk6 by mir-34a induces cell cycle arrest. FEBS Lett. 2008;582:1564–8. doi:10.1016/j.febslet.2008.03.057.
41. Tivnan A, Tracey L, Buckley PG, Alcock LC, Davidoff AM, Stallings RL. MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma. BMC Cancer. 2011;11:33. doi:10.1186/1471-2407-11-33.
42. Ji Q, Hao X, Meng Y, Zhang M, Desano J, Fan D, et al. Restoration of tumor suppressor mir-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer. 2008;8:266. doi:10.1186/1471-2407-8-266.
43. Nalls D, Tang SN, Rodova M, Srivastava RK, Shankar S. Targeting epigenetic regulation of mir-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS One. 2011;6:e24099. doi:10.1371/journal.pone.0024099.
44. Xiao Z, Li CH, Chan SL, Xu F, Feng L, Wang Y, et al. A small-molecule modulator of the tumor-suppressor mir34a inhibits the growth of hepatocellular carcinoma. Cancer Res. 2014;74:6236–47. doi:10.1158/0008-5472.CAN-14-0855.